During renal allograft rejection platelet aggregates form in the glomerular capillaries and small arteries and in the absence of effective treatment become stabilized by fibrin and attached to damaged endothelium and eventually become incorporated into the arterial intima (Porter, 1967; Mustard, Evans, Packham, and Nishizawa, 1969) . Rejection episodes after the tenth day are then characterized by fibrinoid necrosis of the vasculature. Less often frank thrombosis of the renal vessels may accompany immediate rejection resulting from blood group incompatibility or presensitization of the donor (Porter, Dossetor, Marchioro, Peart, Rendall, Starzl, and Terasaki, 1967) .
Under any of these circumstances changes in peripheral blood platelets, fibrinogen, reactive proteins, and fibrinolysis might be evident. We have made detailed studies of these factors over a period of the four weeks following transplantation in nine patients and some less detailed studies in another five. There are also long-term follow-up observations on 12 patients.
Methods
Before operation and on three days a week thereafter estimations were made of platelet counts, plasma fibrinogen (Ratnoff and Menzie, 1951) , fibrin monomer (Lipin'ski, Worowski, Jeljaszewicz, Niewiarowski, and Rejniak, 1968) , euglobulin lysis time (von Kaulla, 1963, modified by Menon), fibrinolytic inhibitors of urokinase (McNichol, Gale, and Douglas, 1962) , and serum fibrin degradation products using the Burroughs Wellcome kit. (The Received for publication 18 June 1970. blood was collected in tubes containing trasylol and was clotted with thrombin.) In addition, serum proteins were measured by radial diffusion in agar plates containing specific antisera against al-antitrypsin, odl-acid glycoprotein and orosomucoid as typical reactant proteins, and against a2-macroglobulin, immunoglobulin IgM and,lC/,BIA complement. These estimations were made without knowledge of the clinical course of the patient, which was being assessed independently by the clinician (P.R.U.) using standard clinical and biochemical criteria.
The clinical criteria for rejection were swelling, pain, and tenderness of the graft accompanied by malaise, fever, tachycardia, hypertension, and decrease in urine output. Some or all of these signs were present in all cases and were supported by a rise in serum creatinine and a fall in urine urea excretion. Rejection was harder to diagnose in patients receiving cadaver grafts with poor initial function due to ischaemia. Renal biopsy was employed in selected cases, especially in those receiving cadaver grafts in which it was difficult to decide whether rejection had been adequately treated. 'Percentage changes are given except for fibrin degradation products which are in ug/ml absolute units (normal less than 20 iAgJml).
'Had nephrectomy only 10 days before graft.
before the tenth day, and 10 rejection episodes occurred after the tenth day in seven patients.
Results
The more important protein changes which became evident in the postoperative period are given in Table II Fibrin degradation products in the colectomy patients rose to about 20 ,ug/ml for 10 days and this slight rise also occurred in the transplant patients but four showed early peaking to 160 ptg/ml, the peak coinciding in patient J.S. with a postoperative collapse of the left lower lobe of the lung, in patient G.H. with suspected early rejection, in M.L. with acute tubular necrosis followed also by rejection, and in patient J.M. with rejection. By the tenth day reactive protein changes were subsiding only to reappear as a sequel to episodes of rejection, extravasation of urine or urinary infection. Both serum complement and IgM were now rising unless a rejection episode occurred, when there was a fall followed by a rise. Six of the nine patients studied in detail and one other had some form of major crisis during this period, and it is of interest that these episodes were accompanied by a peak rise in the fibrin degradation products. These events are summarized in Table III . The value of the fibrin degradation products can be judged from the frequency with which they coincide with rejection. In all there were 22 episodes of fibrin degradation products peaking of which 10 (Table III) 
Rise to normal levels When the patients were seen later as outpatients it was found that by two months of full ambulation the euglobulin lysis time usually returned to the normal range (40-110 units). However, it was less than 40 units in 18 out of 50 random estimations in outpatients. Thus even later the euglobulin lysis time might be intermittently depressed and also at these times outpatients' fibrin degradation products might have risen to 40 ,ug/ml, suggesting that the coincidence was a sign of insidious chronic rejection. Although fibrinolytic inhibitors showed their greatest values in the postoperative phase, they also continued intermittently at high levels in some patients. Figure 1 gives in graphical form some of the details of patient T.L. who illustrates typical features-the postoperative rise in fibrinogen, fibrin monomer, and acl-antitrypsin, together with urokinase inhibitors. Note also the early recovery of the euglobulin lysis time followed by depression, and during this time a rejection episode was accompanied by a rise in fibrin degradation products. Complement and IgM are falling at about this time. Our observation of serum protein reactive changes in the postoperative period agrees with previous studies (Crockson, Payne, Ratcliff, and Soothill, 1966; Werner, 1969, Werner and Cohnen, 1969) . These are non-specific changes due to tissue damage or infection and although they may also occur as a sequel to rejection they are of no help in diagnosis.
The already accepted indices of rejection, namely, decreased urine output and decreased urinary sodium with urinary excretion of alkaline phosphatases and LDH at the time of rise of the serum creatinine, leucocytosis, and graft swelling with tenderness, appear to be adequate (Bergstrom, Blomstrand, Magnusson, and Werner, 1968) . However, as shown in Table II , a fall in plasma fibrinogen in the early postoperative period was associated with early rejection and ischaemic damage (cf McMillan, 1968) . Moreover, a rise in serum fibrin degradation products when accompanied by a fall in platelets (Table III) was associated with rejection and was far more dramatic, albeit a later change, than a fall in complement or IgM (Ziihlke, Deodhar, Nakamoto, and Kolff, 1967; Carpenter, Gill, Merrill, and Dammin, 1967) . A postoperative rise in fibrinolytic inhibitors is also recognized (Tsitouris, Bellet, Eilberg, Feinberg, and Sandberg, 1961) but is normally of limited duration. Fibrinolytic activator was markedly reduced for about eight weeks in our patients, apart from a transient return to normal levels at the time of initial urine production by the graft. Moreover, this could not be explained by inhibitor levels and suggested damage to endothelial cells with failure of production of activator. Inhibition of fibrinolysis for as long as two years has been described by Ljungqvist, Bergentz, Leondoer, and Nilsson (1969) ; these authors also suggest that antibodies might be produced against urokinase but we have been unable to detect such antibodies.
The endothelial cells of the normal kidney have a remarkable fibrinolytic potential (Holemans, Johnston, and Reddick, 1965) and there is some activity in normal arteriolar endothelium (Onoyama and Tanaka, 1969) . It is possible that early loss of fibrinolysis might lead to a more serious type of rejection, as the findings in three of our patients suggest. In fact deposits of IgM and IgG, together with fibrin and complement, are now well recognized as occurring on renal endothelium during rejection (McKenzie and Whittingham, 1969) , together with actual thrombi and progressing to later obliterative lesions in the form of 'endarteritis fibrosa' 
Addendum
Since this work was done it has been reported (Isacson, 1970 ) that prednisone in a dose of 20 mg per day is an inhibitor of plasminogen activator production. This could be the explanation for poor fibrinolysis in these patients.
